Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B

Various treatment combinations of peginterferon (PEG‐IFN) and nucleos(t)ide analogues have been evaluated for chronic hepatitis B (CHB), but the optimal regimen remains unclear.

[1]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[2]  R. D. de Knegt,et al.  Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON) , 2017, The Journal of infectious diseases.

[3]  P. Marcellin,et al.  Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open- , 2017, The lancet. Gastroenterology & hepatology.

[4]  M. Levrero,et al.  Aiming for cure in HBV and HDV infection. , 2016, Journal of hepatology.

[5]  K. Simon,et al.  Peginterferon add‐on results in more HBsAg decline compared to monotherapy in HBeAg‐positive chronic hepatitis B patients , 2016, Journal of viral hepatitis.

[6]  Q. Ning,et al.  Sustained Immune Control in HBeAg-Positive Patients who Switched from Entecavir Therapy to Pegylated Interferon-α2a: 1 Year follow-up of the OSST Study , 2016, Antiviral therapy.

[7]  U. Protzer,et al.  Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure. , 2016, Journal of hepatology.

[8]  E. Remmerswaal,et al.  Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy. , 2016, Journal of hepatology.

[9]  N. Terrault,et al.  AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.

[10]  G. Pedrazzi,et al.  Natural killer cell phenotype modulation and natural killer/T‐cell interplay in nucleos(t)ide analogue‐treated hepatitis e antigen‐negative patients with chronic hepatitis B , 2015, Hepatology.

[11]  C. Yim,et al.  Reduced risk of relapse after long‐term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B , 2015, Alimentary pharmacology & therapeutics.

[12]  K. Simon,et al.  Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study) , 2015, Hepatology.

[13]  M. Buti,et al.  Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection , 2014, Digestive Diseases and Sciences.

[14]  Q. Ning,et al.  Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). , 2014, Journal of hepatology.

[15]  T. Liang,et al.  Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA , 2014, Science.

[16]  D. Ouzan,et al.  Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[17]  C. Chu,et al.  Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients , 2013, Hepatology.

[18]  H. Janssen,et al.  Pegylated Interferon Results in Higher Serological, but Not Virological, Response Rates When Compared to Continuous Entecavir , 2012, Antiviral therapy.

[19]  P. Lampertico,et al.  Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. , 2012, Gastroenterology.

[20]  P. Galle,et al.  Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[21]  M. Dandri,et al.  New insight in the pathobiology of hepatitis B virus infection , 2012, Gut.

[22]  Ying Sun,et al.  Performance of the aspartate aminotransferase‐to‐platelet ratio index for the staging of hepatitis C‐related fibrosis: An updated meta‐analysis , 2011, Hepatology.

[23]  H. Janssen,et al.  Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. , 2011, Journal of hepatology.

[24]  H. Janssen,et al.  Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. , 2010, Gastroenterology.

[25]  K. Simon,et al.  Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. , 2008, Gastroenterology.

[26]  P. Schirmacher,et al.  Peginterferon alpha‐2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B , 2006, Hepatology.

[27]  M. Yuen,et al.  One-Year Entecavir or Lamivudine Therapy Results in Reduction of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA Levels , 2005, Antiviral therapy.

[28]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[29]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[30]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[31]  R. D. de Man,et al.  Long‐term follow‐up of alpha‐interferon treatment of patients with chronic hepatitis B , 2004, Hepatology.